Samuel Pierre

Computer ScienceEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial”.

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial

American Journal of Respiratory and Critical Care Medicine(2024)10.1164/rccm.202311-2004oc

N/A

0.741DataRank · unranked

13 citations

Elisa H. Ignatius, Veronique de Jager, Caryn M. Upton, Soyeon Kim, Ashley McKhann +14 more

A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

The Lancet Infectious Diseases(2025)10.1016/s1473-3099(25)00436-0

N/A

0.315DataRank · unranked

4 citations

Isabelle R. Weir, Kimberly K. Scarsi, Alberto Mendoza‐Ticona, Samuel Pierre, Luke Hall +30 more

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Open Forum Infectious Diseases(2021)10.1093/ofid/ofab559

N/A

0DataRank · unranked

3 citations

Iryna Bocharova, Catherine Nguyen, Fabienne Homeus, Gaetane Julmiste, Youry Macius +12 more

Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings

Open Forum Infectious Diseases(2022)10.1093/ofid/ofac325

N/A

0DataRank · unranked

5 citations

Xin Sun, Sonya Krishnan, Mitch Matoga, Samuel Pierre, Katherine N. McIntire +17 more

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study

The Lancet HIV(2025)10.1016/s2352-3018(25)00162-6

N/A

0DataRank · unranked

3 citations

Caitlyn McCarthy, Carole L. Wallis, Cissy Kityo, Michael D. Hughes, Catherine Godfrey +44 more

Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.108075

N/A

0DataRank · unranked

0 citations

Kelly E. Dooley, Wendy Carr, Jason E. Stout, Eric Nuermberger, Patrick Phillips +22 more